

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18 F-FDG PET and MRI radiomics features**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1709234> since 2019-08-12T13:51:48Z

*Published version:*

DOI:10.1007/s00259-018-4250-6

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

[Click here to view linked References](#)

# Predicting locally advanced rectal cancer response to neoadjuvant therapy with $^{18}\text{F}$ -FDG PET and MRI radiomics features

## Authors

Giannini V<sup>1,2</sup>, Mazzetti S<sup>1,2</sup>, Bertotto I<sup>1</sup>, Chiarenza C<sup>1</sup>, Cauda S<sup>3</sup>, Delmastro E<sup>4</sup>, Bracco C<sup>5</sup>,  
Di Dia A<sup>5</sup>, Leone F<sup>6</sup>, Medico E<sup>7</sup>, Pisacane A<sup>8</sup>, Ribero D<sup>9</sup>, Stasi M<sup>5</sup>, Regge D<sup>1,2</sup>

## Affiliations

<sup>1</sup>Imaging Unit, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 km 3.95, 10060  
Candiolo (TO), Italy

<sup>2</sup>Department of Surgical Sciences, University of Turin, 10124 Turin, Italy

<sup>3</sup>Nuclear Medicine Unit, Candiolo Cancer Institute, FPO-IRCCS

<sup>4</sup>Radiation Therapy Unit, Candiolo Cancer Institute, FPO-IRCCS

<sup>5</sup>Medical Physics Unit, Candiolo Cancer Institute, FPO-IRCCS

<sup>6</sup>Medical Oncology Unit, Candiolo Cancer Institute, FPO-IRCCS

<sup>7</sup>Laboratory of Oncogenomics, Candiolo Cancer Institute, FPO-IRCCS

<sup>8</sup>Pathology Unit, Candiolo Cancer Institute, FPO-IRCCS

<sup>9</sup>Hepatobilio-Pancreatic and Colorectal Surgery Unit, Candiolo Cancer Institute, FPO-IRCCS

## Corresponding author

Valentina Giannini, ORCID 0000-0001-5052-8231

[valentina.giannini@ircc.it](mailto:valentina.giannini@ircc.it)

Tel. +39 011 9933327

# Predicting locally advanced rectal cancer response to neoadjuvant therapy with $^{18}\text{F}$ -FDG PET and MRI ~~radiomier~~radiomics features

## Abstract

**Purpose:** Pathological complete response (pCR) following neoadjuvant chemoradiotherapy or radiotherapy in locally advanced rectal cancer (LARC) is reached in approximately 15-30% of cases, therefore it would be useful to assess if pretreatment  $^{18}\text{F}$ -FDG PET/CT and/or MRI texture features can reliably predict response to neoadjuvant therapy in LARC.

**Methods:** 52 patients were dichotomized as responder (pR+) or non-responder (pR-) according to their pathological ~~tumour~~tumor regression grade (TRG) as follows: 22 as pR+ (9 with TRG=1, 13 with TRG=2) and 30 as pR- (16 with TRG=3, 13 with TRG=4 and 1 with TRG=5). First order parameters and 21 second order texture parameters derived from the Gray-Level Co-Occurrence matrix were extracted from semi-automatically segmented ~~tumour~~tumors on T2-w MRI, ADC maps and PET/CT acquisitions. The role of each texture feature in predicting pR+ was assessed with monoparametric and multiparametric models.

**Results:** In the mono-parametric approach PET homogeneity reached the maximum AUC (0.77; sensitivity=72.7% and specificity=76.7%), while PET glycolytic volume and ADC dissimilarity reached the highest sensitivity (both 90.9%). In the multiparametric analysis, a logistic regression model containing 6 second-order texture features (five from PET and one from T2-w MRI) yields the highest predictivity in distinguish between pR+ and pR- patients (AUC=0.86; sensitivity=86% and specificity=83% at the Youden index).

**Conclusions:** If preliminary results of this study ~~are will be~~ confirmed, pretreatment PET and MRI ~~images~~ could be useful to personalize patient treatment, e.g., avoiding toxicity of neoadjuvant therapy in patients predicted pR-.

**Keywords (4 to 6):** locally advanced rectal cancer,  $^{18}\text{F}$ -FDG PET/CT imaging, Magnetic Resonance Imaging, texture features, prediction of treatment response, radiomics-.

## Introduction

Colorectal cancer is the third leading cause of cancer-related mortality in Western countries and in approximately ~~1/3<sup>rd</sup>~~ one third of cases tumor is localized in the ~~rectum~~ rectum [1]. The standard therapeutic scheme for locally advanced rectal cancer (LARC) involves surgical resection, preceded by neoadjuvant chemoradiotherapy (CRT) or radiotherapy only (RT) [2,3]. Neoadjuvant treatment can reduce the risk of local recurrence, downsize the tumor and facilitate subsequent successful R0 resection and sphincter-preserving surgery [4]. Pathological complete response (pCR) is reached in approximately 15-30% of ~~cases~~ subjects and in these cases a wait-and-see strategy is becoming a viable therapeutic option [5]. To improve patient~~s~~ management, it could be advantageous to determine the likelihood of pCR or near pCR before treatment to allow clinicians to tailor therapy. Importantly, patients predicted non-responders could benefit from alternative treatments~~;~~ or up-front surgery, avoiding toxicity and side effects of CRT/RT.

Recently, the idea has emerged that medical images are like the “dark matter in space”~~;~~ since only a small percentage of image “data” is actually used by the radiologist for interpretation whilst the vast majority is locked up within the images themselves. Radiomics analysis can extract hidden data and process large amounts of information from routinely acquired medical images with the scope of providing a comprehensive quantification of tumor phenotype. Radiomics uses advanced quantitative feature analysis, including analysis of the spatial layout of images and of their geometric shape [6]. Improvement in image analysis through the understanding of its texture properties has revealed important prognostic information on disease course [7,8] and on the understanding of underlying genomic patterns [9].

Texture analysis has been applied to MRI to predict long term survival of patients with ~~locally advanced rectal cancer~~ LARC [10], to discriminate different stages of rectal cancer [11] and also to predict response to CRT [12,13]. The role of texture analysis in predicting response to CRT has also been investigated with <sup>18</sup>F-FDG PET/CT [14,15]. To our knowledge, combining <sup>18</sup>F-FDG-PET and MRI texture features with the aim of predicting which patients with LARC will respond to neoadjuvant therapy has never been attempted before. However, this approach has shown promising results in other tumor models. For example, Vallières et al. [16] have shown that the predictive value of baseline <sup>18</sup>F-FDG-PET texture features in the risk evaluation of lung metastasis at the time of diagnosis of primary soft-tissue sarcomas was significantly enhanced by the addition of MRI parameters.

The aim of this study is to assess if a combination of MRI and <sup>18</sup>F-FDG PET/CT texture features can reliably predict response to neoadjuvant therapy (CRT/RT) in LARC and provide clues that could ultimately improve patient management.

## Materials and Methods

### *Patients*

Subjects with LARC that underwent neoadjuvant CRT or only RT ~~and only~~ followed only by surgical resection at our Institution were retrospectively enrolled in a single institution study between July 2010 and October 2016. Inclusion criteria were the following: a) biopsy-confirmed stage II/III LARC (any T, positive N); b)

1 absence of distant metastasis (M0); c) axial MRI examination, including T2-weighted (T2w) and diffusion  
2 weighted imaging (DWI), and fluoro-D-glucose (FDG) PET performed at our Institute prior to neoadjuvant  
3 treatment. Exclusion criteria were: a) significant image artifacts at MR and/or FDG-PET examinations, b)  
4 absence of tumor regression grading (TRG) evaluation [17], c) age < to 18 years, d) pregnancy, e) mentally  
5 incompetent subjects. The study design was approved by the local Ethics Committee, in accordance with the  
6 Helsinki Declaration; signed informed consent to use and analyze imaging data was obtained from all  
7 participants before entering the study. All accrued patients were evaluated by our internal ~~tumor~~tumor board  
8 before and after the completion of the neoadjuvant treatment.  
9

### 10 11 12 13 14 15 *Treatment*

16 Thirty-two of the 57 patients enrolled in this study were part of a protocol (RectumSIB: ClinicalTrials.gov  
17 identifier: NCT01224392) comparing the standard neoadjuvant radiation treatment (CRT arm; 17 patients) to  
18 an exclusive radiotherapy treatment protocol with a simultaneous integrated boost (RT arm; 15 patients), as  
19 previously reported [18]. The remaining 25 patients performed standard CRT treatment with the same technical  
20 specification of the RectumSIB protocol. Six to eight weeks after the end of ~~radiotherapy~~radiotherapy, all  
21 patients repeated the MRI examination of the rectum and FDG-PET and subsequently underwent total  
22 mesorectal excision (TME).  
23  
24  
25  
26  
27

### 28 29 *Reference standard*

30 Resected ~~tumor~~tumors were evaluated by an experienced pathologist. All surgical specimens were received  
31 under vacuum sealing ~~and~~; stored at 4 °C; within 2 hours from the resection. The specimens were then opened;  
32 and the tumor bed was macroscopically identified and extensively sampled at 5 mm intervals. Tissue slices  
33 were then fixed in 10% buffered formalin at room temperature for 24 h and ~~subsequently then~~paraffin  
34 embedded. Semiserial sectioning at 0.5 mm intervals from each tissue slice from the tumor bed was performed  
35 and the sections stained with hematoxylin and eosin for microscopic examination. Semi-quantitative  
36 pathological evaluation of primary tumor regression was performed, determining the ~~namount/a~~number  
37 of residual tumor cells compared with the desmoplastic response, using the Mandard's five-point assessment  
38 scheme [19].  
39  
40  
41  
42  
43  
44  
45

46 In this system TRG 1 represents a complete regression (=fibrosis without detectable tissue of tumor); TRG 2  
47 represents a partial response (rare residual tumor cells); TRG 3 is defined as fibrosis outgrowing residual  
48 tumor; TRG 4 is defined as residual tumor outgrowing fibrosis; TRG 5 represents a complete non response  
49 (absence of regressive changes).  
50  
51  
52  
53

### 54 *Imaging*

55 MRI was performed with a 1.5T scanner using an 8-channel phased-array surface coil (HDx Signa Excite, GE  
56 HealthCare Milwaukee, WI, USA). Patients were positioned in the supine position and, unless contraindicated,  
57 a 20 mg intramuscular injection of butyl-scopolamine was administered intravenously 10 minutes before the  
58 beginning of the examination, to minimize motion artefact induced by bowel peristalsis. The acquisition  
59  
60  
61  
62  
63  
64  
65

1 protocol included a fast spin echo T2w sequence acquired on the axial plane perpendicular to the longest  
2 ~~tumour~~tumor diameter having the following scanning parameters: repetition/echo time (TR/TE) = 7660/110  
3 ms, acquisition matrix=416x224, slice thickness=4 mm, pixel size=0.4297x0.4297 mm<sup>2</sup>, field of view=22 cm,  
4 and flip angle=90°, ~~and as well as~~ an axial EPI-SE Diffusion Weighted (DW) sequence with the following  
5 scanning characteristics: TR/TE = 2000/87 ms, acquisition matrix= 96x128, slice thickness= 4 mm, pixel  
6 size=0.8594x0.8594 mm<sup>2</sup>, field of view= 22 cm, flip angle=90°, ~~and~~ b-value= 800 s/mm<sup>2</sup>. Total examination  
7 time including a sagittal and a coronal T2w sequence and a dynamic contrast enhanced T1w sequence was 31  
8 minutes.  
9

10  
11  
12  
13 FDG-PET was performed using a PET-CT Gemini TF scanner (Philips Medical System, Cleveland, OH) with  
14 Time-of-Flight (TOF) technology. All studies were carried out ~~following~~ according to the European  
15 Association of Nuclear Medicine (EANM) guidelines [19]. Before the ~~examination~~examination, patients fasted  
16 for a minimum of 6 hours and were required to have a serum glucose concentration ~~lower than~~below 200 ng/dl.  
17 ~~Intravenous administration of a~~ weight-based amount of [18F]FDG, with standard dose of 2.5 MBq/kg ~~was~~  
18 ~~injected~~. After 60 minutes of rest, patients were asked to void bladder and were placed in supine position with  
19 arms raised. Image acquisition time was 15-20 minutes.  
20  
21  
22  
23  
24

### 25 26 *Image segmentation*

27  
28 We developed an algorithm using C++ and the ITK libraries to segment tumors on MR images [20]. The  
29 semi-automatic segmentation method was applied on both the T2w and the DW images. First, a bounding box  
30 enclosing the rectal region (Figure 1a) was drawn manually on the T2w images. Second, the bounding box  
31 was automatically applied to both T2w and DW images to crop the two datasets along the same physical  
32 coordinates (Figure 1b-c). ~~Subsequently~~, a k-means algorithm was applied on both datasets. The k-means  
33 method is an unsupervised learning algorithm that classifies a given dataset through a *k* number of clusters, in  
34 which each observation is associated with the cluster having the closest mean. In our algorithm, we defined  
35 *k*=3 for the T2w sequence and *k*=5 for the DW image. On the T2w images, the cluster having the lowest  
36 mean intensity value is more likely to contain voxels belonging to the tumor, while on the DW images the 2 clusters  
37 with the highest intensity values ~~more likely~~ belong ~~more likely~~ to non-necrotic areas of the tumor- (Figure  
38 1d-e). Therefore, the final segmentation was composed ~~of~~by voxels belonging to the tumoral region in both  
39 T2w/DW datasets (Figure 1f-g), i.e., the intersection between the two segmentations (figure 1h). ~~Finally~~, the  
40 ~~2D biggest connected region~~ is kept as the final region of interest, while other non-connected regions (i.e.,  
41 noise, vessels, ~~regions and regions~~ outside the tumor) are discarded. Once the automatic segmentation was  
42 completed, an experienced radiologist (more than 10 years of experience in interpreting abdominal MRI)  
43 manually reviewed the results of segmentation on both T2w and ADC maps to include missing voxels and/or  
44 to exclude voxels that were erroneously included by the algorithm (Figure 1i).  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

57 Segmentation of tumors on PET images was obtained using the previously described automatic Adaptive  
58 Threshold Algorithm [21]. First, a background area close to the lesion was drawn by a nuclear medicine  
59 physician, then the algorithm iteratively determined a threshold value based on the percentage of the maximum  
60  
61  
62  
63  
64  
65

intensity in the cross-section area of a sphere containing the tumor. The threshold values were entirely based on the apparent activity concentration in the images and not on known activities. On our dataset the threshold values ranged from 0.737 to 16.848. Finally, all masks were reviewed by an expert nuclear medicine physician.

### Features extraction

The following ~~radiomic~~radiomics features were extracted from voxels belonging to the segmented 2D mask in the T2w, ADC and PET images: a) 5 first order parameters, i.e. mean intensity, median intensity, 10<sup>th</sup>, 25<sup>th</sup> and 75<sup>th</sup> percentile; b) 21 second order texture parameters derived from the Gray-Level Co-Occurrence matrix (GLCM); c) ~~the mean standard uptake volume (SUV<sub>mean</sub>), the~~ metabolic volume, defined as the area of the segmented PET mask, and ~~the~~ glycolytic volume, which is the product between metabolic volume and SUV<sub>mean</sub>.

The GLCM is a tabulation of how often different combinations of pixel brightness values (i.e. grey levels) occur between ~~neighbouring~~neighboring voxels in an image. Therefore, the GLCM allows the calculation of second order texture features, i.e., describing the relationship between groups of contiguous pixels in the image. To extract the texture parameters, we first equalized the histogram by rescaling the intensities within each ROI between the 1st and the 99th percentile of the ROI over 64 bins. Using 64 equally divided bins has been a common approach for image quantification in radiomics analysis, and at the same ~~time~~time, it ~~allows~~makes it possible to explore the whole range of ~~tumour~~tumor signal intensities [22] ~~y~~ [10.1016/j.ijrobp.2017.12.268]. Then, GLCMs were generated for each of the four directions of a 2D image, considering the distance between two ~~neighbouring~~neighboring voxels equal to one. Finally, the 4 matrices were averaged ~~to enable the method to be rotationally invariant~~to make the method rotationally invariant to the distribution of texture. ~~y~~. Texture features were computed using the MATLAB and Statistics Toolbox Release 2016b (The MathWorks, Inc., Natick, Massachusetts, United States).

### Statistical analysis

Patients were dichotomized as responders (pR+), having TRG=1 or 2, vs non-responders (pR-) having TRG≥3. The relationship between pR+/pR- and texture features was explored ~~both~~by ~~both~~ the mono-parametric and multi-parametric approach. When using the first approach, we evaluated the predictive value of each feature individually, using the Mann-Whitney test. For those variables that were statistically different between pR+ and pR- patients, we evaluated ~~the~~AUC, area under the receiver operating characteristic (ROC) curve (AUC), ~~(AUC)~~sensitivity, and specificity at the best cut-off. Sensitivity was defined as the number of correctly classified pR+ patients over the total number of pR+ patients, while specificity was defined as the number of correctly classified pR- patients over the total number of pR- patients. The best cut-off ~~is the one that~~ maximizes the Youden index, which is the cut-point of the ROC curve that optimizes the biomarker's differentiating ability when equal weight is given to sensitivity and specificity [23]. A p-value < 0.05 was considered as indicating a significant AUC greater than 0.5. Analyses were performed with ~~a~~ statistical software (MedCalc Statistical Software version 17.4, Ostend, Belgium).



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Conversely, in the multiparametric approach, the accuracy in predicting pR+ of different feature subsets was assessed using a logistic classifier. Three feature subsets were created composed of: a) features from MRI images (T2w and ADC maps), b) features from PET images, and c) features from both MRI and PET images. However, since the dimensionality of features was high for all ~~the~~ three subsets, a feature selection step was necessary to exclude irrelevant or redundant attributes that might cause overfitting and that might be a source of noise for the classifier [24]. To this scope, features were first ranked according to their AUC in discriminating between pR+ and pR-; ~~subsequently then,~~ the correlation matrix between features was computed, to detect which pairs were highly correlated. When a couple of features showed a Pearson's linear correlation  $\geq 0.8$ , we discarded the feature with the lower AUC. To improve stability and avoid bias, this selection was repeated 100 times using random training sets composed of 80% of the whole patients' dataset. Only features ~~that were chosen~~ chosen more than 60 times were included in the subsequent analysis. Once the three subsets of features were created, they were fed into a logistic classifier, applying the stepwise regression method, to further exclude irrelevant variables. Within this procedure, the method searches for terms to add to or remove based on the p-value of the F-statistics and iteratively add or remove terms that have p-value  $\leq 0.05$  and/or p-value  $> 0.20$ , respectively. Sensitivity, and specificity, as previously defined, were then estimated.

## Results

### *Patients*

From the initial cohort of 57 patients, 3 were excluded due to MRI artifacts and 2 because the TRG score was not evaluated. The final dataset included 52 patients, of whom 35 men (68%). Twenty-two patients were classified pR+ (9 with TRG=1, 13 with TRG=2), the remaining 30 were classified as pR- (16 with TRG=3, 13 with TRG=4 and 1 with TRG=5). Patient and lesion characteristics are reported in Table 2. Of note, age was statistically lower in the pR+ group, grade 0 and 1 ~~tumors~~ tumors were more represented in the pR+ group, grade 3 and 4 were more represented in the pR- group, pT0 ~~tumors~~ tumors were significantly more represented in the pR+ group while pT3 were significantly more represented in pR- group.

### *Mono-parametric approach*

In total 12 features derived from PET images and 5 features computed on the ADC maps accurately response to neoadjuvant therapy (table 3). The maximum AUC (0.77) was obtained by PET homogeneity, ~~which, that~~ also showed a good balance between sensitivity (72.7%, 16/22) and specificity (76.7%, 23/30). Lower values of the PET homogeneity feature were measured in responders ( $< 0.18$ ). The highest sensitivity in the prediction of response was obtained by PET glycolytic volume and ADC dissimilarity (both 90.9%; 20/22) at the cost of a low specificity (56.8% [17/30] and 43.3% [13/30], respectively). Conversely, the specificity in response prediction was obtained by metabolic volume (83.3% [25/30]) to the detriment of sensitivity (63.6% [14/22]). Figure 2A shows ROC curves of PET and ADC features having the highest values and reaching the highest sensitivities. T2w features did not differ between responders and non-responders with the mono-parametric approach (



Fig. 2).

Fig. 3 shows the mean AUC reached by each radiomics features computed on PET, T2w and ADC images during the 100 repetitions. Features from PET images obtained higher AUCs compared to features from MRI images. The median AUC obtained by texture features from PET was 0.65 (IQR= 0.61-0.73); from T2w image was 0.57 (IQR= 0.56-0.58); and from ADC maps was 0.59 (IQR=0.57 - 0.63).

### *Multi-parametric approach*

The feature selection step returned 3 features subsets composed of: a) features from PET images, b) features from MRI images, c) features from both PET and MRI images. Features included in each subset are listed in Table 1 (column 2-4).

The logistic classifier obtained using only PET features included homogeneity, contrast, metabolic volume, glycolytic volume, and 10<sup>th</sup> percentile, and reached an AUC of 0.84, a sensitivity and a specificity at the Youden index (0.5) of 77% (17/22) and 83% (25/30), respectively. In order to obtain the highest sensitivity in predicting pR+, i.e., ensuring treatment to the large majority of responder patients, we could lower the cut-off value. With a cut-off value of 0.28 we obtained a sensitivity of 91% (20/22) and a specificity of 57% (17/30) in recognizing responder patients. When only features from MRI images were used, the logistic regression created a model containing 10<sup>th</sup> percentile and correlation-1 from T2w images and cluster prominence and information measure of correlation 2 from the ADC maps. This model reached an AUC of 0.72, and a sensitivity and specificity of 73% (16/22) and 70% (21/30) respectively, at the Youden index (0.37). Finally, when features from PET and MRI images were combined, the logistic regression computed a model containing: PET homogeneity, PET contrast, PET 10<sup>th</sup> percentile, glycolytic volume, metabolic volume, and T2w correlation1. The AUC obtained by this model was 0.86, while sensitivity and specificity at the Youden index (0.42) were 86% (19/22) and 83% (25/30), respectively. When lowering the cut-off to 0.25 the model will correctly recognize as responder one additional patient (sensitivity 91%; 20/22) but at the expense of a marked reduction in specificity (53%; 16/30) (see Figure 2B).

### **Discussion**

In this study we show that a logistic regression model containing 5 second-order PET texture features and one second-order texture feature from the T2 MRI sequence yields the highest predictivity in determining which patients will or will not respond to neoadjuvant therapy (AUC=0.86). However, the combined PET-MRI regression model yielded results that were only slightly better than a model including only 5 PET features (AUC=0.84) and far better than a model including only MRI features (AUC=0.72). If FDG-PET will be confirmed as a reliable predictor of response, then hybrid PET-MRI imaging could be implemented in the future be implemented both to stage LARC and to tailor treatment to the individual patient.

In the above described regression models the Youden index allows determination of the best cut-off value between sensitivity and specificity. However, from a clinical standpoint a high sensitivity value

1 would ensure that most patients that will benefit from CRT treatment actually receive it, even if this will come  
2 at the cost of a large group of patients having to undergo treatment unnecessarily. In our ~~study~~ study, the highest  
3 sensitivity was obtained by lowering the cut-off value of the ROC curve of the multiparametric PET model to  
4 0.28. Assuming we were in clinical practice, the PET model would have correctly suggested the use of CRT  
5 in over 9 out of 10 patients (i.e. 91% sensitivity) and ~~have~~ avoided unnecessary treatment in almost 6 of 10  
6 patients (i.e. 57% specificity).  
7

8  
9 Of note, the AUC was lower for each first or second order features taken individually. Overall, PET  
10 homogeneity yielded the best results with an AUC of 0.77 followed by PET inverse difference normalized and  
11 ADC entropy. Based on current knowledge an explanation cannot be given to why patients with metabolically  
12 inhomogeneous LARC respond better to neoadjuvant treatment; however, a similar trend was also reported  
13 by Lovinfosse et al. [14]. We might envisage that molecular traits of tumor may be responsible for poor  
14 response and that combining molecular and imaging metrics will allow better comprehension ~~on of~~ the  
15 mechanisms that underlie tumor objective response. One additional finding of this study is that we confirm  
16 that **dissimilarity and contrast directly correlate** with good response, while metabolic volume and glycolytic  
17 volume inversely **correlate** with good response to RT as previously demonstrated by other authors ~~which who~~  
18 adopted a different method, i.e., odds ratio, to evaluate correlation between individual features and response  
19 to CRT instead of ROC analysis [14,15].  
20

21  
22 There are some points of strength of this study that deserve consideration. First, ~~unlike opposite to~~ most  
23 previous studies on the assessment of radiomics features of LARC [12,25], in this study not only first but also  
24 second order features were extracted to assess tumor characteristics. Second order features provide information  
25 on the spatial relations between neighboring regions/voxels of the tumor, which first order features, such as  
26 ~~histogram derived~~ histogram-derived features cannot explore. Lovinfosse et al [14] showed that histogram  
27 features failed to independently predict outcome measures in multivariate analysis. Contrarily, the same  
28 authors identified coarseness, a local textural feature that quantifies granularity of tumor, as a predictor of  
29 disease free survival [14]. Second, multi-variate analysis was performed to identify groups of features that  
30 were more predictive of response to treatment than individual parameters. Third, the collection of PET and  
31 MRI images we used were all from the same institution, ~~taken~~ on the same equipment and using the same  
32 exam protocols, ensuring a high reproducibility of test. Fourth, to our knowledge this is the first time that PET  
33 and MRI features have been combined in a single classifier with the aim of predicting response to neoadjuvant  
34 therapy in LARC, with promising results. For data ~~analysis~~ analysis, we used the original image instead of  
35 filtered images as in Dinapoli et al. [25]. ~~Using~~ original images avoids including bias in the original data and  
36 allows exploitation of a larger number of texture parameters.  
37

38  
39 There are also limitations to this work. First, our results should be validated on data originating from different  
40 scanners and different acquisition protocols. Second, texture analysis was performed on the largest single-slice  
41 mask rather than on the whole tumor. ~~However~~ However, whether the decision to use the whole dataset or only  
42 the slice most representative of the tumor to measure radiomics features has long been debated and  
43 which is best has not been convincingly determined. Indeed, Ng et al. [26] [PMID: 23194641], in a study  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 involving 55 patients with primary colorectal cancer, showed that entropy computed on CT images was higher  
2 and uniformity lower for the whole tumor volume compared to the largest cross-sectional area at all filter levels  
3 ~~and~~ Kaplan Meier analysis showed better separation of entropy and uniformity for whole tumor analysis for  
4 5-year overall survival. ~~Nevertheless~~ However, findings of other Authors appear to be going in a different  
5 direction [27] ~~[PMID: 28881840]~~. Lubner et al. [28] ~~[PMID: 25968046]~~, for example, compared 2D and 3D  
6 texture features from CT images in a subset of 20 patients with hepatic metastatic colorectal cancer and  
7 demonstrated that overall results were fairly similar in Bland–Altman analysis (e.g., for entropy, the limits of  
8 agreement were -0.0182, 0.029, bias 0.005). Also, in a larger study involving 588 patients with non-small cell  
9 lung cancer, Shen et al. [29] ~~[PMID: 28930698]~~ demonstrated that 2D texture features performed slightly better  
10 in discriminating between high and low risk tumors, thus suggesting their use in clinical practice since they  
11 are less time-consuming and do not require heavy-load computation ~~as needed for the~~ 3D analysis.  
12 Moreover, 2D analysis has been previously demonstrated ~~asto be~~ a robust prognostic tool to provide important  
13 information for patients<sup>2</sup> management [30,31,32,33,34,35]. ~~[PMID: 28523352, PMID: 28707546, PMID:~~  
14 ~~25768265, PMID: 26971430, PMID: 21943720, PMID: 21102348]~~.  
15 ~~There are several~~ Several advantages of 2D analysis ~~that~~ may be worthwhile addressing. First, in a clinical  
16 perspective where time is an important issue, 2D analysis is more straightforward ~~than~~ 3D analysis, ~~both~~  
17 ~~if whether~~ performed manually or via semi-automatic segmentation. Second, in the specific setting of rectal  
18 cancer, 3D segmentation of 2D MRI images may not be accurate, in particular on the cranial and caudal  
19 margins of the lesion due to low tissue contrast on T2w images and low spatial resolution of DWI.  
20 In our study, we tried to reduce reader variability by automatically detecting the largest slice of the tumor and  
21 semi-automatically segmenting it. The final segmentation required a minimal user<sup>2</sup>s intervention and might be  
22 easily integrated in clinical practice, providing a straightforward tool for ~~a~~ better management of patients.  
23 Currently, we are working on the implementation of a deep learning algorithm to automatically segment rectal  
24 cancers on MR images, and, if successful, ~~in the future~~ we will ~~in the future~~ test this algorithm to extract 3D  
25 texture features, comparing the results with our current findings of 2D analysis.  
26 ~~We will evaluate differences between the 2D and the 3D approach as the next step.~~ Third, we used a semi-  
27 automatic method for segmentation of the tumor, which cannot completely avoid inter-reader variability.  
28 However, this is the first study attempting to perform a semi-automatic segmentation, which is a very  
29 challenging task due to the low contrast between tumor and healthy regions.  
30 In conclusion, in this study we explore the potential role of texture parameters derived from pretreatment MRI  
31 and PET images in predicting the response to CRT/RT in patients with ~~locally advanced rectal cancer~~ LARC.  
32 These preliminary results, if confirmed, could be useful to personalize patient treatment, for example ~~avoiding~~  
33 ~~to avoid~~ toxicity of neoadjuvant therapy in patients predicted non responders.

## 56 Acknowledgements

1 This work was funded by ~~FPRC 5 per mille 2015 Ministero della Salute and by AIRC MultiUnit 5 per Mille~~  
2 ~~grant (number 21091). "AIRC 5xmille Special Program Molecular Clinical Oncology - Ref.9970" and "FPRC~~  
3 ~~5xmille 2013 Ministero Salute". and "Ricerca Corrente 2018".~~

#### 6 **Compliance with Ethical Standards**

7  
8 Funding: ~~This work was funded by "AIRC 5xmille Special Program Molecular Clinical Oncology - Ref.9970"~~  
9 ~~and "FPRC 5xmille 2013 Ministero Salute". and "Ricerca Corrente 2018". This study was funded by FPRC 5~~  
10 ~~per mille 2015 Ministero della Salute and by AIRC MultiUnit 5 per Mille grant (number 21091).~~

11  
12  
13  
14  
15 Conflict of Interest: All authors declare that they have no conflict of interest.

16  
17  
18 Ethical approval: All procedures performed in studies involving human participants were in accordance with  
19 the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki  
20 declaration and its later amendments or comparable ethical standards.

21  
22  
23  
24  
25 Informed consent: Informed consent was obtained from all individual participants included in the study.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

TABLES

Table 1: List of features computed on T2w and PE-T images. "X" in columns 2,3,4 show features that have been chosen in the features-selection step on each features\_subset.

	<b>Features</b>	<b>PET</b>	<b>MRI</b>	<b>PET+MRI</b>
FIRST ORDER	mean intensity			
	median intensity			
	10 <sup>th</sup> percentile	<b>X</b>	<b>X (T2w)</b>	<b>X (PET,T2w)</b>
	25 <sup>th</sup> percentile			
	75 <sup>th</sup> percentile			
	Metabolic volume (PET)	<b>X</b>		<b>X (PET)</b>
Glycolytic volume (PET)	<b>X</b>		<b>X (PET)</b>	
GLCM	autocorrelation [36]			
	contrast [37]	<b>X</b>	<b>X (ADC)</b>	<b>X (PET, ADC)</b>
	correlation 1 [36]		<b>X (T2w)</b>	<b>X (T2w)</b>
	correlation 2 [37]			
	cluster prominence [36]	<b>X</b>	<b>X (ADC, T2w)</b>	<b>X (PET, T2w, ADC)</b>
	cluster shade [36]		<b>X (ADC)</b>	<b>X (ADC)</b>
	Dissimilarity [36]		<b>X (T2w)</b>	
	Energy [37]	<b>X</b>		<b>X (PET)</b>
	Entropy [36]			
	Homogeneity [37]	<b>X</b>	<b>X (T2w)</b>	<b>X (PET)</b>
	maximum probability [37]			
	variance [37]		<b>X (T2w)</b>	<b>X (T2w)</b>
	sum variance [37]			
	sum entropy [37]	<b>X</b>	<b>X (T2w)</b>	<b>X (PET, T2w)</b>
	sum average [37]			
	difference variance [37]			
	difference entropy [37]			
information measure of correlation 1 [37]	<b>X</b>	<b>X (ADC)</b>	<b>X (PET, ADC)</b>	
information measure of correlation 2 [37]				
inverse difference normalized [38]				
inverse difference moment normalized [38]				

Table 2: Patients and lesions characteristics

	All (n = 52)	pR+ (n = 22)	pR- (n = 30)	p-value
Age	68 (60-74)	63 (57-70)	71 (63-75)	0.05 <sup>a</sup>
<b>Sex</b>				
Men	35	14 (40.0%)	21 (60.0%)	0.662 <sup>b</sup>
Women	17	8 (47.1%)	9 (52.9%)	0.662 <sup>b</sup>
<b>Histological type</b>				
Adenocarcinoma	42	17 (40.5%)	25 (59.5%)	0.607 <sup>b</sup>
Mucinous cancer	9	5 (55.6%)	4 (44.4%)	0.370 <sup>b</sup>
Villous adenoma	1	0 (0.0%)	1 (100.0%)	0.711 <sup>b</sup>
<b>Grading</b>				
0	4	4 (100.0%)	0 (0.0%)	<b>0.013<sup>b</sup></b>
1	4	4 (100.0%)	0 (0.0%)	<b>0.013<sup>b</sup></b>
2	27	6 (22.2%)	21 (77.8%)	<b>0.003<sup>b</sup></b>
3	10	1 (10.0%)	9 (90.0%)	<b>0.021<sup>b</sup></b>
Not Evaluated	7	7 (100.0%)	0 (0.0%)	n.a.
<b>Post CRTpathologic T stage</b>				
0	9	9 (100.0%)	0 (0.0%)	<b>&lt;0.001<sup>b</sup></b>
1	5	3 (60.0%)	2 (40.0%)	0.510 <sup>b</sup>
2	14	6 (42.9%)	8 (57.1%)	0.877 <sup>b</sup>
3	22	3 (13.6%)	19 (86.4%)	<b>&lt;0.001<sup>b</sup></b>
4	1	0 (0.0%)	1 (100.0%)	0.711 <sup>b</sup>
Tis	1	1 (100.0%)	0 (0.0%)	0.211 <sup>b</sup>
<b>Post CRTpathologic nodal status</b>				
0	42	20 (47.6%)	22 (52.4%)	0.118 <sup>b</sup>
Positive	10	2 (80.0%)	8 (80.0%)	0.118 <sup>b</sup>

pR+=Mandard stage $\leq$ 2; pR-= Mandard stage $\geq$ 3. Age and tumour size are expressed as median with interquartile ranges in parentheses, while other measurements are expressed as counts with percentages in parenthesis. <sup>a</sup> p-value of the Mann-Whitney test. <sup>b</sup> p-value of the Fisher's exact mid-P test.

Table 3: Area under the ROC curve, sensitivity, specificity, Youden Index and p-value of feature that were statistically different between pR+ and pR- groups. INN=Inverse difference moment; IDMN= Inverse difference moment normalized. Sensitivity and specificity are expressed as percentage, within the number of patients in parentheses.

		AUC	Sensitivity	Specificity	Criterion	p-value
<b>PET</b>	<b>Homogeneity</b>	0.771	72.7 (16/22)	76.7 (23/30)	<0.18	<0.001
	<b>Dissimilarity</b>	0.745	81.8 (18/22)	60.0 (18/30)	>4.3	<0.001
	<b>INN</b>	0.744	72.7 (16/22)	70.0 (21/30)	<0.935	<0.001
	<b>Glycolytic Volume</b>	0.741	90.9 (20/22)	56.7 (17/30)	<1.549*10 <sup>6</sup>	<0.001
	<b>IDMN</b>	0.736	68.2 (15/22)	80.0 (24/30)	<0.9915	<0.001
	<b>Difference Variance</b>	0.736	68.2 (15/22)	76.7 (23/30)	>34.2	0.001
	<b>Contrast</b>	0.736	68.2 (15/22)	76.7 (23/30)	>34	0.001
	<b>Sum entropy</b>	0.735	63.6 (14/22)	80.0 (24/30)	>4.665	0.001
	<b>Metabolic volume</b>	0.73	63.6 (14/22)	83.3 (25/30)	<486	0.001
	<b>Difference entropy</b>	0.706	77.3 (17/22)	66.7 (20/30)	>2.47	0.005
	<b>Energy</b>	0.698	77.3 (17/22)	60.0 (18/30)	<0.0016	0.007
	<b>Maximum probability</b>	0.668	86.4 (19/22)	43.3 (13/30)	<0.008	0.027
<b>ADC</b>	<b>Difference entropy</b>	0.683	86.4 (19/22)	50.0 (15/30)	>1.98	0.014
	<b>Homogeneity</b>	0.682	77.3 (17/22)	56.7 (17/30)	<0.34	0.015
	<b>Dissimilarity</b>	0.679	90.9 (20/22)	43.3 (13/30)	>2.349	0.018
	<b>INN</b>	0.679	77.3 (17/22)	56.7 (17/30)	<0.963	0.017
	<b>Entropy</b>	0.656	68.2 (15/22)	70.0 (21/30)	>6.35	0.045



## FIGURE CAPTIONS

1  
2  
3 **Fig 1** Pipeline of the tumor segmentation on the T2w image. a) T2w image; b) cropped T2w image; c) cropped  
4 DW image; d) k-means applied on the T2w image; e) k-means applied on the DW image; f) thresholding to  
5 extract tumoral cluster on the T2w image; g) thresholding to extract tumoral cluster on the DW image; h)  
6 intersection between k-means mask f) and g); i) final mask refined by the radiologist and superimposed to the  
7 T2w image  
8  
9

10  
11 **Fig. 2** (A) Receiver Operating Characteristic (ROC) curves of PET and ADC features having the highest areas  
12 under the ROC curve and the highest sensitivities; (B) **radiomieradiomics signature** score for every patient: the  
13 green marks indicate the patients in the responder group, while the red marks represent the patients in the non-  
14 responder group (B). Dotted line is the threshold which optimize sensitivity over specificity  
15  
16  
17  
18

19 **Fig. 2** Heatmap shows the normalized mean difference of **radiomieradiomics features** distributions between  
20 pR+ and pR- for both MRI (T2w and ADC) and PET images. \* indicates features statistically different between  
21 pR+ and pR- patients (p-value<0.05) using a two-sided Mann-Whitney test  
22  
23  
24

25 **Fig. 3** Area under the receiver operating characteristics (ROC) curve reached by each of radiomics features  
26 computed on both PET and MRI (T2w and ADC) images. ROCs were computed 100 times using random  
27 training sets composed of 80% of the whole patients' dataset. Means and standard deviations are showed.  
28 IMC= Information measure of correlation; INN = Inverse difference moment; IDNN = Inverse difference  
29 moment normalized  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65


## REFERENCES



- [1] Siegel R, Miller KD, Jemal A. Cancer statistics, 2017. *CA Cancer J Clin.* 2017; 67: 7-30.
- [2] NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer, Version 1.2016 NCCN.org. ; 2016.
- [3] Sauer R, Becker H, Hohenberger W, et al. Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. *New England Journal of Medicine.* 2004; 351(17): 1731-1740.
- [4] Li Y, Wang J, Ma X, Tan L, Yan Y, Xue C, et al. A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. *Int J Biol Sci.* 2016; 12(8): 1022-1031.
- [5] Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. *Lancet Oncol.* 2010; 11: 835-844.
- [6] Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: extracting more information from medical images using advanced. *Eur J Cancer.* 2012; 48(4): 441-6.
- [7] Diehn M, Nardini , Wang S, McGovern , Jayaraman , Liang , et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. *Proc. Natl Acad. Sci. USA.* 2008; 105(13): 5213-8.
- [8] Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C4, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative. *Nat Commun.* 2014; 5: 4006.
- [9] Coroller TP, Grossmann P, Hou Y, Rios Velazquez E, Leijenaar RT, Hermann G, et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. *Radiother Oncol.* 2015; 114(3): 345-350.
- [10] Jalil O, Afaq A, Ganeshan B, Patel UB, Boone D, Endozo R, et al. Magnetic resonance based texture parameters as potential imaging biomarkers for predicting long-term survival in locally advanced rectal cancer treated by chemoradiotherapy. *Colorectal Dis.* 2017; 19(4): 349-362.
- [11] Liu L, Liu Y, Xu L, Li Z, Lv H, Dong N, et al. Application of texture analysis based on apparent diffusion coefficient maps in discriminating different stages of rectal cancer. *J Magn Reson Imaging.* 2017; 45(6): 1798-1808.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [12] De Cecco CN, Ganeshan B, Ciolina M, Rengo M, Meinel FG, Musio D, et al. Texture analysis as imaging biomarker of tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3-T magnetic resonance.. *Invest Radiol.* 2015; 50(4): 239-45.
- [13] Cusumano D, Dinapoli N, Boldrini L, Chiloiro G, Gatta R, Masciocchi C, et al. Fractal-based radiomic approach to predict complete pathological response after chemo-radiotherapy in rectal cancer. *Radiol Med.* 2017; [Epub ahead of print].
- [14] Lovinfosse P, Polus M, Van Daele D, Martinive P, Daenen F, Hatt M, et al. FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer. *Eur J Nucl Med Mol Imaging.* 2017.
- [15] Bundschuh R, Dinges J, Neumann L, Seyfried M, Zsótér N, Papp L, et al. Textural Parameters of Tumor Heterogeneity in <sup>18</sup>F-FDG PET/CT for Therapy Response Assessment and Prognosis in Patients with Locally Advanced Rectal Cancer. *J Nucl Med.* 2014; 55(6): 891-7.
- [16] Vallières M, Freeman CR, Skamene SR, El Naqa I. A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. *Phys Med Biol.* 2015; 60(14): 5471-96.
- [17] Mandard A, Dalibard F MJMJHAM, Petiot JF, Roussel A, Jacob JH, Segol P, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. *Cancer.* 1994; 73(11): 2680-6.
- [18] Engels B, De Paoli A, Cattari G, Munoz F, Vagge S, Norkus D, et al. Preoperative Radiotherapy with a Simultaneous Integrated Boost Compared to Chemoradiation therapy for T3-4 Rectal Cancer: Interim Analysis of a Multicentric Randomized Trial. *International Journal of Radiation Oncology - Biology - Physics.* 2014; 90(1): S22-S23.
- [19] Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. *Eur J Nucl Med Mol Imaging.* 2010; 37(1): 181-200.
- [20] Johnson HJ, McCormick M, Ibanez L. *The ITK software guide.* 3rd ed.: Kitware Inc.; 2013.
- [21] M. Brambilla MR, Basile C, Bracco C, Castiglioni I, Cavedon C, et al. An Adaptive Thresholding Method for BTV Estimation Incorporating PET Reconstruction Parameters: A Multicenter Study of the Robustness and the Reliability. *Comput Math Methods Med.* 2015; 2015(571473).

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [22] Cook GJR, Azad G, Owczarczyk K, Siddique M, Goh V. Challenges and Promises of PET Radiomics. *Int J Radiat Oncol Biol Phys*. 2018; 102(4): 1083-1089.
- [23] Youden WJ. Index for rating diagnostic tests. *Cancer*. 1950; 3: 32-35.
- [24] Chizi B, Maimon O. Dimension Reduction and Feature Selection. In Maimon O, Rokach L. *Data Mining and Knowledge Discovery Handbook*.: Springer, Boston, MA; 2005. 93-111.
- [25] Dinapoli N, Barbaro B, Gatta R, Chiloiro G, Casà C, Masciochi C, et al. Magnetic Resonance, vendor-independent, intensity histogram analysis predicting. *International Journal of Radiation Oncology • Biology • Physics*. 2018; in press.
- [26] Ng F, Kozarski R, Ganeshan B, Goh V. Assessment of tumor heterogeneity by CT texture analysis: can the largest cross-sectional area be used as an alternative to whole tumor analysis? *Eur J Radiol*. 2013; 82(2): 342-8.
- [27] Liu Y, Liu S, Qu F, Li Q, Cheng R, Ye Z. Tumor heterogeneity assessed by texture analysis on contrast-enhanced CT in lung adenocarcinoma: association with pathologic grade. *Oncotarget*. 2017; 8(32): 53664-53674.
- [28] Lubner MG, Stabo NLSJ, del Rio AM, Song C, Halberg RB, Pickhardt PJ. CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes. *Abdom Imaging*. 2015; 40(7): 2331-7.
- [29] Shen C, Liu ZGM, Song J, Lian Y, Wang S, Tang Z, et al. 2D and 3D CT Radiomics Features Prognostic Performance Comparison in Non-Small Cell Lung Cancer. *Transl Oncol*. 2017; 10(6): 886-894.
- [30] Henderson SPCMC, Evans A, Lerski R, Johnston M, Vinnicombe S, Thompson AM. Interim heterogeneity changes measured using entropy texture features on T2-weighted MRI at 3.0 T are associated with pathological response to neoadjuvant chemotherapy in primary breast cancer. *Eur Radiol*. 2017; 27(11): 4602-4611.
- [31] Giannini V, Mazzetti S, Marmo A, Montemurro F, Regge D, L M. A computer-aided diagnosis (CAD) scheme for pretreatment prediction of pathological response to neoadjuvant therapy using dynamic contrast-enhanced MRI texture features. *Br J Radiol*. 2017; 90(1077): 20170269.
- [32] Vignati A, Mazzetti S, Giannini V, Russo F, Bollito E, Porpiglia F, et al. Texture features on T2-weighted magnetic resonance imaging: new potential biomarkers for prostate cancer aggressiveness. *Phys Med Biol*. 2015; 60(7): 2685-701.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [33] Skogen K, Schulz A, Dormagen JB, Ganeshan B, Helseth E, Server A. Diagnostic performance of texture analysis on MRI in grading cerebral gliomas. *Eur J Radiol.* 2016; 85(4): 824-9.
  - [34] Ganeshan B, Skogen K, Pressney ICDMK. Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. *Clin Radiol.* 2012; 67(2): 157-64.
  - [35] Ganeshan B, Burnand K, Young R, Chatwin C, Miles K. Dynamic contrast-enhanced texture analysis of the liver: initial assessment in colorectal cancer. *Invest Radiol.* 2011; 46(3): 160-8.
  - [36] Soh L, Tsatsoulis C. Texture Analysis of SAR Sea Ice Imagery Using Gray Level Co-Occurrence Matrices. *IEEE Transactions on Geoscience and Remote Sensing.* 1999; 37(2): 780-795.
  - [37] Haralick RM, Shanmugam K. Textural features for image classification. *IEEE Trans Syst Man Cybern.* 1973; SMC-3: 610-21.
  - [38] Clausi DA. An analysis of co-occurrence texture statistics as a function of grey level quantization. *Can. J. Remote Sensing.* 2002; 28(1): 45-62.










Figure 4

